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Transcription factor 2 gene (TCF2) encodes hepatocyte nuclear factor 1b (HNF1b), a transcription factor associated with
development and metabolism. Mutation of TCF2 has been observed in renal cell cancer, and by screening aberrantly methylated
genes, we have now identified TCF2 as a target for epigenetic inactivation in ovarian cancer. TCF2 was methylated in 53% of ovarian
cancer cell lines and 26% of primary ovarian cancers, resulting in loss of the gene’s expression. TCF2 expression was restored by
treating cells with a methyltransferase inhibitor, 5-aza-20deoxycitidine (5-aza-dC). In addition, chromatin immunoprecipitation showed
deacetylation of histone H3 in methylated cells and, when combined with 5-aza-dC, the histone deacetylase inhibitor trichostatin A
synergistically induced TCF2 expression. Epigenetic inactivation of TCF2 was also seen in colorectal, gastric and pancreatic cell lines,
suggesting general involvement of epigenetic inactivation of TCF2 in tumorigenesis. Restoration of TCF2 expression induced
expression of HNF4a, a transcriptional target of HNF1b, indicating that epigenetic silencing of TCF2 leads to alteration of the
hepatocyte nuclear factor network in tumours. These results suggest that TCF2 is involved in the development of ovarian cancers and
may represent a useful target for their detection and treatment.
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Ovarian cancer is the most deadly of gynecological malignancies,
with an overall 5-year survival rate of o30%. In large part, this is
because the disease usually presents at an advanced stage, as there
are no overt symptoms at early stages. Ovarian cancers are
morphologically and biologically heterogeneous and associated
with distinct genetic alterations. For example, the serous type
frequently shows p53 mutations, the mucinous type K-ras
mutations, and the endometrioid type b-catenin mutations. The
molecular pathogenesis of ovarian cancer is not fully understood,
however, and it is hoped that a better understanding of the
molecular mechanisms underlying the tumorigenic process will
lead to earlier diagnosis, novel therapies and, ultimately, better
outcomes.
DNA methylation can be a good molecular marker by which to
identify genes inactivated in cancer (Jones & Baylin, 2002; Laird,
2003; Issa, 2004; Costello, 2005), and several techniques, including
restriction landmark genome scanning and methylation-sensitive
arbitrary primer PCR, have been used to screen for aberrantly
methylated DNA fragments in tumour cells (Zardo et al, 2002; Yu
et al, 2005). In addition, we have developed a novel methylation
screening technique, methylated CpG island amplification (MCA),
which we have used to identify DNA fragments that are
hypermethylated in cancer (Toyota et al, 1999). And by coupling
MCA to representational difference analysis (RDA) we have been
able to identify those genes inactivated by hypermethylation
(Toyota et al, 1999; Ueki et al, 2001; Obata et al, 2003; Palmisano
et al, 2003; Yamada et al, 2004). When we used MCA in
combination with RDA to screen for genes methylated in an
ovarian cancer cell line, we observed for the first time that
transcription factor 2 gene (TCF2) is a target for epigenetic
inactivation.
TCF1 and TCF2, respectively, encode the transcription factors
hepatocyte nuclear factor 1a and b (HNF1a and HNF1b), two
POU-homeodomain proteins that bind to an essential element in
the proximal promoter sequences of albumin and many other
tissue-specific genes and are associated with development,
metabolism and cancer (Cereghini et al, 1987; Courtois et al,
1987; Frain et al, 1989; Rey-Campos et al, 1991). For instance,
TCF2 defects cause developmental abnormalities in multiple
tissues, including kidney and pancreas (Horikawa et al, 1997;
Haumaitre et al, 2005), and Bluteau et al (2002) identified biallelic
mutations of TCF1 in hepatic adenomas (Bluteau et al, 2002).
Subsequently, mutations of TCF1 also were found in colorectal
cancer with MSI (Laurent-Puig et al, 2003) and endometrial
tumours (Rebouissou et al, 2004), while Rebouissou et al (2005)
also identified mutations of TCF2 in renal carcinomas.
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sWith that as background, our aim in the present study was to
evaluate TCF2 methylation in panels of ovarian cancer cell lines
and primary ovarian cancers. Our findings indicate that TCF2
expression is lost in ovarian cancer cell lines that show
methylation and that expression is restored by treating cells with
a methyltransferase inhibitor, confirming epigenetic silencing of
the gene. Moreover, restoration of TCF2 expression induced
expression of HNF4a, a transcriptional target of HNF1b, indicating
that epigenetic silencing of TCF2 leads to alteration of the
hepatocyte nuclear factor network in tumours. These results
suggest that epigenetic inactivation of TCF2 is involved in
development of ovarian cancer.
MATERIALS AND METHODS
Cell lines and specimens
Eight ovarian cancer cell lines (SKOV-3, OVCAR-3, PA-1, Caov-3,
TOV112D, TOV21G, SW626, OV-90), eight colorectal cancer cell
lines (RKO, HCT116, DLD-1, LoVo, HT29, Colo320, SW480,
Colo205), and eight gastric cancer cell lines (MKN7, MKN45,
MKN74, JRST, KatoIII, AZ521, NUGC3, NUGC4), were obtained
from the American Tissue Culture Collection (Manassas, VA, USA)
or the JCRB (Tokyo, Japan). Seven pancreatic cancer cell lines
(MIAPACA2, PK-3, PK1NC, PK-8, CF-PAC, PK-9, PK-45) were
obtained from American Tissue Culture Collection or from Cell
Resource Center for Biomedical Research, Institute of Develop-
ment, Aging and Cancer, Tohoku University (Sendai, Japan). Seven
other ovarian cancer cell lines (MH, KURA, AMOC-2, MCAS, KF,
KFr, HTBOA) were described previously (Ishiwata et al, 1986;
Kikuchi et al, 1986), as was the cervical cancer cell line (OMC-1)
used (Ueda et al, 1989). All cell lines were cultured in RPMI 1640
(Life Technologies Inc., Rockville, MD, USA) supplemented with
10% fetal bovine serum and incubated under a 5% CO2
atmosphere at 371C. Two cell lines that showed aberrant
methylation and diminished gene expression were treated with
the indicated concentration of the methyltransferase inhibitor
5-aza-20deoxycitidine (5-aza-dC) for 96h and/or the histone
deacetylase inhibitor trichostatin A (TSA) for 24h. The cells were
then harvested and the total RNA extracted using Isogen
(Nippongene, Tokyo, Japan). In addition, four samples of normal
ovarian tissue and 98 ovarian cancer specimens were obtaining
from Sapporo Medical University Hospital at surgery and stored at
–801C. In accordance with institutional guidelines (Ishioka et al,
2003), all patients gave informed consent prior to collection of the
specimens.
MCA/RDA
MCA was carried out as described previously (Toyota et al, 1999).
We used the MCA amplicon from the OVCAR-3 ovarian cancer cell
line as a tester and that from normal ovarian tissue as a driver.
After two rounds of subtraction by RDA, the PCR products were
digested with XmaI and ligated to pBluescriptII (Stratagene). The
inserts were then sequenced using an ABI3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Database analysis was
performed using Blast and BLAT.
Bisulphite treatment of genomic DNA
Genomic DNA was isolated from cell lines and primary tissue
samples (cancerous and normal) using the phenol–chloroform
method and then treated with sodium bisulphite as described
previously (Clark et al, 1994). Briefly, 2mg of DNA were denatured
for 10min at 371Ci n2 M NaOH, after which 30mlo f1 0 m M
hydroquinone (Sigma Chemical Co, St Louis, MO, USA) and 520ml
of 3 M sodium bisulphite were added. The mixture was then
incubated for 16h at 501C, and the modified DNA was purified
using a Wizard DNA Purification System (Promega, Madison, WI,
USA). After treating the DNA with NaOH a second time, the
resultant DNA precipitate was resuspended in 20ml of TE buffer
and stored at  801C until use.
Combined bisulphite restriction analysis
The methylation status of TCF2 was examined using combined
bisulphite restriction analysis (COBRA), a semiquantitative
bisulphite-PCR analysis (Xiong & Laird, 1997). Primers were
designed so that both methylated and unmethylated DNA would be
amplified equally. PCR was carried out in a 50-ml volume
containing 1  PCR buffer (67mM Tris-HCl (pH 8.8), 16.6mM
(NH4)2SO4, 6.7mM MgCl2, and 10mM b-mercaptoethanol),
0.25mM dNTP mixture, 0.5mM each primer and 1.0U of Hot Start
Ex-Taq polymerase (TaKaRa). The oligonucleotide sequences used
for bisulphite-PCR were 50-GGGGTYGAGTTYGATATTAAGT-30
(TCF2COBRA-F) and 50-TACCTAAACATCCRATCCACCT-30
(TCF2COBRA-R). The PCR products were digested with the
restriction enzyme TaiI (Fermentas Life Sciences, Ontario,
Canada), which cleaves CpG sites retained because of methylation.
After ethanol precipitation, the DNA was subjected to 2.5% agarose
gel electrophoresis and stained with ethidium bromide.
Direct-sequencing of Bisulphite-PCR products
The PCR products obtained with COBRA were used for direct-
sequencing. Briefly, 10ml of bisulphite-PCR product were electro-
phoresed in 1% SeaPlaque agarose gel, excised, purified using a
PCR Purification System (Promega, Madison, WI, USA) and eluted
in 50ml of water. Samples (5ml) were then used as templates for the
sequencing reaction, which was carried out using a BigDye
terminator cycle sequencing kit (Applied Biosystems, Foster City,
CA, USA) with an ABI PRISM 3100 sequencer according to the
manufacturer’s guidelines (Applied Biosystems).
Reverse transcription–polymerase chain reaction
Expression of TCF2 and HNF4a was analyzed using reverse
transcription–polymerase chain reaction (RT—PCR). Total RNA
was extracted from cell lines using Trizol (Life Technologies Inc.,
Gaithersburg, MD, USA) according to the manufacturer’s instruc-
tions. The RT reaction was carried out with 2mg of total RNA using
a SuperScript II First-Strand Synthesis System (Invitrogen Inc.,
Grand Island, NY, USA) with random primer. PCR was carried out
in solution containing 1  PCR buffer (TaKaRa), 200mM each
deoxynucleotide triphosphate, 2.5pmol of each primer, 1U of
ExTaq polymerase (TaKaRa) and 5% (v/v) DMSO. The oligo-
nucleotide primer sequences used were 50-CTATGACACACCTCC
CATCCTCAAG-30 (TCF2RT-F), 50-GTCTGGTTGAATTGTCGGAG
GATCT-30 (TCF2RT-R), 50-CGGCAGTGCGTGGTGGACAAAGAC-30
(HNF4-aRT-F), and 50-CACACACATCTGCGATGCTGGCAAT-30
(HNF-4aRT-R). The PCR cycling protocol consisted of 1 cycle at
951C for 5min and 32 cycles at 951C for 30s, 601C for 30s and 721C
for 45s. The housekeeping gene GAPDH served as an internal
control to confirm the success of the RT reaction. The PCR
products were subjected to 2.5% agarose gel electrophoresis.
For quantitative analysis, real-time PCR was carried out using a
TaqMan PCR system (Applied Biosystems). PCR was carried out in
50ml of solution containing 1ml of cDNA, 2.5pmol of each primer
and 25ml of TaqMan PCR mixture (Applied Biosystems). The PCR
cycling protocol consisted of 1 cycle at 951C for 5min and 40 cycles
at 951C for 30s and 601C for 1min. Fluorescent signals were
detected using an ABI 7000 Prism 7000 (Applied Biosystems), and
the accumulation of PCR product was measured in real time as the
increase in the fluorescent signal. Data were analysed using ABI
Prism 7000 SDS Software (Applied Biosystems). The probes and
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TCF2 and Hs00230853 for HNF4a (Applied Biosystems).
Mutational analysis
In all, 10 pairs of primers for individually amplifying and
screening exons 1–9 of TCF2 were used for amplifying genomic
DNA. Spanning the entire coding region of the gene, these primers
were specified by a Human BLAT Search (Chr17q12, position:
33,120,547–33,179,182), and their sequences are available upon
request. PCR was carried out in a 50-ml reaction mixture
containing 1 PCR buffer (TaKaRa), 1mM primers, 0.25mM dNTP
mixture and 1.0U of Hot Start Taq polymerase (TaKaRa). The
amplified PCR products were electrophoresed in 1% Seaplaque
gels, excised, purified using a Gel purification system (Qiagen,
Hilden, Germany) and sequenced. The primer sequences and PCR
conditions used for mutational analysis are available upon request.
Chromatin immunoprecipitation and PCR
Chromatin immunoprecipitation was carried out as described
previously (Ueno et al, 2004). Briefly, cells were incubated in 1%
formaldehyde for 10min at 371C. The nuclei were then collected,
sonicated to yield fragments ranging in size from 300 to 2000bp,
and immunoprecipitated with anti-histone H3 antibody (Upstate
Biotechnology, Lake Placid, NY, USA), which specifically recog-
nizes the diacetylated lysine residues (lysines 9 and 14) of histone
H3. The chromatin was recovered using protein A Sepharose. Real-
time PCR was then performed using 1ml of chromatin DNA as
shown above. The primer sequences used were 50-TGGATTT
GGGGTTTGCTTGTGA-30 (TCF2ChIP-F) and 50-GACGTGAGCTT
GGACACCATTTTC-30 (TCF2ChIP-R). Standard curves relating
initial template copy number to fluorescence and amplification
cycle were generated using the amplified PCR product as a
template, and were used to calculate the DNA copy number in each
sample. Ratios of the intensities of the TCF2 and GAPDH signals
were used as a relative measure of the level of TCF2 expression in
each specimen.
Statistical analysis
The statistical analysis was carried out using StatView software
(SAS Institute Inc., Cary, NC, USA). Fisher’s exact test (two-sided)
was used to determine the association between TCF2 methylation
and clinicopathological features. Values of Po0.05 were consid-
ered significant. Overall survival time was defined as the period
between the diagnosis of ovarian cancer and the time of death.
Differences between survival curves were assessed by Kaplan–
Meier analysis using the log-rank test.
RESULTS
Identification of TCF2 as a target for epigenetic
inactivation in ovarian cancer
Using MCA coupled with RDA, we recovered DNA fragments
located within intron 1 of TCF2 (Figure 1A). The 50 region of TCF2
contains a CpG rich region that fulfills the criteria for a CpG island
(observed CpG: expected CpG¼0.821, GC content 58.9%, length
3.4kb). Then when we used COBRA to examine the methylation
status of this region in 15 ovarian and one cervical cancer cell line
(Figure 1B), we found it to be densely methylated in eight (53%) of
the ovarian cancer cell lines, but not in the cervical cancer cell line.
Moreover, using the same methodology, we determined that TCF2
was aberrantly methylated in 26 of 98 (26.5%) primary ovarian
cancers, but not in any of the four samples of normal ovarian
tissue analysed (Figure 1C). Apparently, methylation of TCF2 is a
cancer-specific event and is not a cell line-specific one.
To confirm whether the methylation detected by COBRA reflects
the overall level of methylation in the 50 region of TCF2, we carried
out bisulphite-sequencing of the gene (Figure 2A and B). Again,
methylation of TCF2 was not detected in normal ovarian tissues.
On the other hand, the ovarian cancer cell lines shown by COBRA
to be methylated also showed dense methylation over all their CpG
islands, while those shown by COBRA not to be methylated
showed no methylation of their CpG islands (Figure 2A and B). To
determine whether methylation of TCF2 is correlated with gene
silencing, we used RT–PCR to evaluate the gene’s expression in 15
ovarian and one cervical cancer cell lines (Figure 3). No expression
of TCF2 was detected in any of the nine cell lines that showed
methylation; that is, methylation was significantly associated with
an absence of TCF2 mRNA (Po0.001, Fisher’s exact test, two-
sided). By contrast, all seven cell lines that showed no methylation
expressed the transcript, indicating a role for DNA methylation in
the silencing of TCF2.
To determine whether TCF2 is inactivated by mutation, we first
carried out direct sequence analysis of TCF2 using DNA from
Chromosome 17q.12
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Figure 1 Identification of TCF2 as a target for methylation in ovarian
cancers. (A) Schematic diagram of the CpG island of TCF2. The
chromosomal region in which TCF2 is situated is shown at the top. Vertical
bars indicate CpG sites. Exon is shown by a solid box with an arrow
indicating the transcription start site. The region analysed using COBRA and
the position of the clone obtained with MCA are shown by respective
horizontal bars. (B) Analysis of TCF2 methylation in ovarian cancer cell lines
using COBRA. PCR products contain a restriction site for TaiI, which
recognizes ACGT. The PCR products are digested only when the CpG
sites were retained after bisulphite treatment because of methylation. The
cell lines tested are shown on the top. M: methylated alleles. (C) Analysis of
TCF2 methylation in primary ovarian cancer. The numbers of the cases are
shown above.
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amplified exons 1–9, we examined 15 cell lines and 33 primary
ovarian tumours, and discovered two base substitutions in
the introns, which were determined to be polymorphisms (data
not shown, and Supplementary Figure 1). Thus, inactivation of
TCF2 appears to be caused by epigenetic changes rather than
genetic ones.
Silencing of TCF2 in human tumour cell lines
We next carried out COBRA using DNA from a panel of
human cancer cell lines to determine the frequency with which
TCF2 was methylated in other tumour types (Figure 4A).
Methylation of TCF2 was detected in six of eight (75%) colorectal,
four of eight (50%) gastric and six of seven (85.7%) pancreatic
cancer cell lines (Figure 4B). Moreover, as in ovarian cancer,
expression of TCF2 was absent in cell lines that showed
methylation. One colorectal cancer cell line, DLD-1, also did
not express TCF2, although this cell line did not show meth-
ylation.
The role of DNA methylation and histone deacetylation in
the silencing of TCF2
The role of DNA methylation in the silencing of TCF2 was further
confirmed by our finding that treating cells with the methyl-
transferase inhibitor 5-aza-dC (1mM) restored gene expression. Of
four methylated cell lines tested, all showed restored TCF2
expression following treatment with 5-aza-dC (Figure 5A). By
contrast, expression of TCF2 was not restored by the histone
deacetylase inhibitor TSA, but when combined with a low dose of
5-aza-dC, TSA exerted a synergistic effect augmenting gene
expression (Figure 5B). Using ChIP assays to examine the
acetylation status of histone H3, we found that DNA methylation
was associated with a low level of histone acetylation, indicating
that histone deacetylation, too, plays a role in the silencing of TCF2
(Figure 5C).
The role of TCF2 methylation in the regulation of HNF4a
We next evaluated the expression of HNF4a, one of the
transcriptional targets of HNF1b, in cell lines with and without
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Figure 2 Bisulphite-sequencing analysis of TCF2 in ovarian cancer cell lines. (A) PCR products used for COBRA analysis were electrophoresed in agarose,
excised, purified and directly sequenced. In normal ovary and TOV112D and MCAS cells, all of the cytosines within the CpG sites were substituted with
thymines. In AMOC2, KFr, Caov-3 and HTBOA cells, all cytosines in the CpG sites remained cytosines. In PAI-1 cells, the CpG sites contained a mixture of
cytosines and thymines, as methylation was partial. U: unmethylated CpG sites; M: methylated CpG sites. (B) Summary of bisulphite-sequencing.
Unmethylated CpG sites are indicated by open circles, and methylated CpG sites are indicated by filled circles. CpG sites that show a mixed pattern of
methylated and unmethylated alleles are shown in the grey circles. Cell lines are indicated on the left. The CpG sites in the region analysed are indicated by
vertical bars (top). The CpG site examined by COBRA analysis is indicated as TaiI.
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sTCF2 methylation (Figure 6A). Expression of HNF4a was detected
in all cancer cell lines that expressed TCF2. By contrast, cell lines
that showed TCF2 methylation showed little or no HNF4a
expression. Notably, treating cells with 5-aza-dC upregulated
expression of HNF4a (Figure 6B and C). As the 50 region of
HNF4a does not contain a CpG island, the effect of 5-aza-dC on the
gene’s expression is likely not associated with demethylation of its
promoter, but instead underscores the importance of TCF2
expression, and thus HNF1b, in the regulation of HNF4a.
Clinicopathological features of primary ovarian cancer
with or without TCF2 methylation
Finally, we examined the clinicopathological features of ovarian
cancers with and without TCF2 methylation (Table 1). Aberrant
methylation of TCF2 was detected in 12 of 29 (41.3%) serous
tumours, three of 12 (25.0%) mucinous tumours, eight of 28
(28.6%) endometrioid tumours and three of 12 (25.0%) others
(undifferentiated, mixed type), but in none of the 17 (0%) clear cell
tumours. Methylation of TCF2 was detected significantly less
frequently in the clear cell phenotype than the other types (0% vs
32.1%, Fisher’s Exact test, P¼0.005), but there was no significant
association with any other clinicopathological feature (patients’
age, FIGO clinical stage, and pathological grade). There was also no
correlation between the patients’ prognoses and the TCF2
methylation status (data not shown, and Supplementary Figure 2).
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Figure 5 Silencing of TCF2 is associated with DNA methylation and
histone deacetylation. (A) Restoration of TCF2 mRNA expression by 5-
aza-dC. RT–PCR showed reactivation of TCF2 mRNA expression in two
ovarian and two gastrointestinal cancer cell lines following treatment with
2mM of 5-aza-dC for 72h. (B) Synergistic effect of 5-aza-dC and TSA. PAI-I
and HTBOA ovarian cancer cells were treated with 5-aza-dC and/or TSA,
after which TaqMan PCR was carried out. (C) Acetylation status of histone
H3 in cell lines with and without TCF2 methylation. Acetylation of histone
H3 was assessed using ChIP assays followed by real-time PCR. In both
(B, C) levels of TCF2 mRNA are normalised to those of GAPDH mRNA.
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sDISCUSSION
The transduction network associated with tumorigenesis and the
progression of ovarian cancer is not fully understood, although
numerous studies indicate that DNA methylation plays a key role
in human neoplasia (Jones & Baylin, 2002; Laird, 2003; Issa, 2004;
Costello, 2005). Although methylation of several cancer-related
genes has been reported in ovarian cancer (Yu et al, 1999;
Terasawa et al, 2004), the methylated genes have not yet been fully
characterised. Using the MCA genome screening technique
coupled with RDA, we identified TCF2 as a novel target of
epigenetic inactivation through methylation in ovarian cancer. The
Methylation of TCF2 was cancer-specific and, together with
histone deacetylation, may be involved in tumorigenesis in a
subset of ovarian cancers. It has been reported that patients with
germ line mutation of TCF2 develop renal tumours (Bellanne-
Chantelot et al, 2004), and TCF2 mutations have been identified in
renal cell cancer (Rebouissou et al, 2005). On the other hand, no
TCF2 mutation has been previously observed in ovarian cancer
(Rebouissou et al, 2005), which is consistent with our present
finding that TCF2 is not mutated in ovarian cancer. Apparently,
TCF2 expression is silenced by an epigenetic rather than genetic
mechanism. That methylation of TCF2 was also detected in
colorectal, gastric and pancreatic cancer cell lines suggests TCF2 is
prone to methylation in many types of cancer and may thus play a
general role in tumorigenesis. In addition, one ovarian cancer cell
line, TOV112D, and one colorectal cancer cell line, DLD-1, did not
express TCF2, although little or no methylation was detected in
tumours. Genes silenced in cancer are often not expressed in
cancer cell lines (Suzuki et al, 2002), and their silencing may be
caused by mechanisms other than methylation, for example by the
absence of a transcription factor or histone modification (Kondo
et al, 2004).
The methylation profile of ovarian cancer may be a useful
diagnostic marker with which to predict recurrence, resistance to
chemotherapy and survival (Balch et al, 2004). We and others have
reported that TMS1, 14-3-3sigma and WT1 genes are methylated
more frequently in clear cell tumours than in other tumour types
(Kaneuchi et al, 2004; Terasawa et al, 2004; Kaneuchi et al, 2005),
whereas methylation of SFRP1, 18S and 28S ribosomal DNA genes
is more frequently detected in nonclear cell tumours, such as the
serous type (Takada et al, 2004; Chan et al, 2005). Although the
molecular mechanisms responsible for the differing methylation
profiles in different tumour types remains unclear, gene methyla-
tion may have relevance in the clinical situation. For instance, clear
cell ovarian cancers are reportedly more resistant to chemotherapy
than other types (Sugiyama et al, 2000), and this difference in
sensitivity may be caused in part by differences in the genes
methylated in clear cell and nonclear cell tumours. In fact,
Teodoridis et al (2005) reported that methylation of genes involved
in DNA repair was significantly associated with response to
chemotherapy, while Chan et al (2005) reported that methylation
of 18S and 28S ribosomal DNA genes is associated with longer
progression-free survival in ovarian cancer. Taken together, these
results suggest that differences in the epigenetic signatures
between clear cell and other types of ovarian cancer may be a
useful diagnostic indicator.
The specific role of TCF2 methylation in the development and
progression of ovarian cancer remains unknown, but TCF2
mutations are known to affect expression of downstream genes
such as HNF4a, PKHD1 and UMOD (Tanaka et al, 2004;
Rebouissou et al, 2005). We showed expression of HNF4a to be
well correlated with that of TCF2 and to be upregulated by
inducing TCF2 expression using a methyltransferase inhibitor,
which suggests alterations in the hepatocyte nuclear factor network
can be reversed by inducing TCF2 through demethylation of the
gene. Consistent with that idea, Lazarevich et al (2004) reported
that expression of HNF4a is downregulated in hepatocellular
carcinoma and its restoration suppresses tumour growth. It has
also been reported that HNF4a is downregulated in other types of
tumours (Lemm et al, 1999) and that it induces expression of
Table 1 Clinicopathological features of ovarian cancer with and without
methylation of TCF2
Methylated (%) Unmethylated (%)
Stage
a
I 8 (25.8) 23 (74.2)
II 1 (33.3) 2 (66.7)
III 15 (26.3) 42 (73.7)
IV 2 (25) 5 (75)
Histology
b
Serous 12 (41.4) 17 (58.6)
Mucinous 3 (25.0) 9 (75.0)
Endometrioid 8 (28.6) 20 (71.4)
Clear cell 0 (0) 17 (100)
Others 3 (25.0) 9 (75.0)
aMethylation of TCF2 was not associated with the stage of the tumours.
bMethylation
of TCF2 was less frequently observed in clear cell types than other types (P¼0.005,
Fisher’s exact test, two-sided).
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Figure 6 Analysis of HNF4a mRNA expression. (A) Expression of
HNF-4a in cancer cell lines and normal tissues was analysed by RT–PCR.
Cell lines, TCF2 methylation statuses, and tissue types are shown on the
top. PAI-1, HTBOA and MKN74 cells were treated with 5-aza-dC (Aza-
dC) and examined for restoration of HNF-4a.( B) Quantitative analysis of
HNF-4a mRNA expression using real-time PCR. Levels of HNF-4a mRNA
were normalised to those of GAPDH mRNA.
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sendothelial Fas ligand (FasL), which prevents cancer cell
transmigration (Osanai et al, 2002). Collectively then, the
summarised findings suggest that impairment of the HNF1b/
HNF4a signalling network may lead to tumour formation. Similar
epigenetic inactivation of a critical regulator of a transcriptional
network has been reported for several other genes, including
estrogen receptor (Leu et al, 2004) and GATA (Akiyama et al,
2003). Epigenetic inactivation of such transcription factors may
affect multiple downstream genes, causing aberrant alteration of
signalling pathways involved in a wide array of cellular functions,
including growth, differentiation and apoptosis. Conversely,
restoration of such transcription factors may lead to upregulation
of genes throughout the entire signalling network and restoration
of proper function. That said, further study will be necessary to
definitively determine the role of epigenetic inactivation of TCF2 in
the molecular mechanism of tumorigenesis and progression of
ovarian cancer and its utility as a therapeutic target.
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